



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 15994

Title: Utility of a Low Accelerating Dose Regimen of Pegylated Interferon alpha-2a and Ribavirin in 182 Liver Transplant Recipients with Recurrent HCV: A Single Centre Study with Long-Term Follow Up

Reviewer's code: 03015785

Reviewer's country: England

Science editor: Yuan Qi

Date sent for review: 2014-12-21 16:01

Date reviewed: 2015-01-04 01:19

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Lim et al present a single-centre study with long-term follow-up regarding a Low Accelerating Dose Regimen of Peg IFN alpha-2a plus RBV for treatment of HCV recurrence after liver transplantation. Even though, the introduction of DAA has improved the outcome of HCV recurrence treatment, there is still need for interferon-based regimen where these new drugs are unavailable. Thus, I think this topic is still of interest for target readers of the journal. However, there are some minor points that should be added into the revised manuscript before acceptance for publication.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 15994

Title: Utility of a Low Accelerating Dose Regimen of Pegylated Interferon alpha-2a and Ribavirin in 182 Liver Transplant Recipients with Recurrent HCV: A Single Centre Study with Long-Term Follow Up

Reviewer's code: 00050195

Reviewer's country: Israel

Science editor: Yuan Qi

Date sent for review: 2014-12-21 16:01

Date reviewed: 2015-01-23 09:14

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors have written an excellent paper on their experience with a low-dose accelerating regimen of pegylated alpha-interferon alpha-2-a and ribavirin in patients with recurrent hCV infection following liver transplantation. This is an important paper , well written and makes a significant contribution to the accumulated experience in the literature. I have no major comments and recommend to accept as is, with a high priority for publication.